TP53 Mutation Characteristics and Their Effects on Overall Survival in AML and MDS

被引：0
|
作者：
Puzo, Christian [1 ]
Hager, Karl [1 ]
Rinder, Henry [1 ]
Weinberg, Olga [2 ]
Siddon, Alexa [1 ]
机构：
[1] Yale Sch Med, New Haven, CT USA
[2] UT Southwestern Med Ctr, Dallas, TX USA
来源：
LABORATORY INVESTIGATION | 2024年 / 104卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
1180
引用
收藏
页码：S1468 / S1470
页数：3
相关论文
共 50 条
  • [1] Overall survival in TP53-mutated AML and MDS
    Puzo, Christian J.
    Hager, Karl M.
    Rinder, Henry M.
    Weinberg, Olga K.
    Siddon, Alexa J.
    ANNALS OF HEMATOLOGY, 2024, 103 (12) : 5359 - 5369
  • [2] Is TP53 Mutated AML the Same Disease as TP53 Mutated MDS?
    Valk, Peter J. M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S3 - S5
  • [3] Clonal Suppression of TP53 Mutant MDS and Oligoblastic AML with Hypomethylating Agent Therapy Improves Overall Survival
    Sallman, David A.
    Al Ali, Najla
    Yun, Seongseok
    Padron, Eric
    Song, Jinming
    Hussaini, Mohammad Omar
    Talati, Chetasi
    Sweet, Kendra L.
    Lancet, Jeffrey E.
    List, Alan F.
    Komrokji, Rami S.
    BLOOD, 2018, 132
  • [4] TP53 in MDS and AML: Biological and clinical advances
    Zhao, Yeqian
    Chen, Weihao
    Yu, Jing
    Pei, Shanshan
    Zhang, Qiang
    Shi, Jimin
    Huang, He
    Zhao, Yanmin
    CANCER LETTERS, 2024, 588
  • [5] Clinical, Cytogenetic and Molecular Characterization of a 96 MDS and AML Cohort with TP53 Mutation
    Duranjou, Marine
    Castoldi, Cecile
    Alary, Anne Sophie
    Hicheri, Yosr
    Saillard, Colombe
    Rouzaud, Camille
    Charbonnier, Aude
    Mohty, Bilal
    D'Incan, Evelyne
    Rey, Jerome
    Devillier, Raynier
    Vey, Norbert
    Gelsi-Boyer, Veronique
    Lhoumeau, Anne-Catherine
    Murati, Anne
    Golesi, Florence
    Mozziconacci, Marie Joelle
    Ittel, Antoine
    Garciaz, Sylvain
    BLOOD, 2023, 142
  • [6] The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases
    A Stengel
    W Kern
    T Haferlach
    M Meggendorfer
    A Fasan
    C Haferlach
    Leukemia, 2017, 31 : 705 - 711
  • [7] The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases
    Stengel, A.
    Kern, W.
    Haferlach, T.
    Meggendorfer, M.
    Fasan, A.
    Haferlach, C.
    LEUKEMIA, 2017, 31 (03) : 705 - 711
  • [8] TP53 in AML and MDS: The new (old) kid on the block
    Marks, Jennifer A.
    Wang, Xin
    Fenu, Elena M.
    Bagg, Adam
    Lai, Catherine
    BLOOD REVIEWS, 2023, 60
  • [9] TP53 and the star-crossed lovers MDS and AML
    Welch, John S.
    BLOOD, 2022, 139 (15) : 2265 - 2266
  • [10] Transplant Outcomes for TP53 AML and MDS in a Contemporary Era
    Ozcan, Gonca
    Popat, Uday R.
    Kebriaei, Partow
    Alousi, Amin M.
    Alatrash, Gheath
    Bashir, Qaiser
    Mehta, Rohtesh S.
    Ramdial, Jeremy L.
    Rondon, Gabriela
    Shpall, Elizabeth J.
    Champlin, Richard E.
    Oran, Betul
    BLOOD, 2022, 140 : 10620 - 10621
12345